Biologics in rheumatoid arthritis - recommendations for Swiss practice.
| Data(s) |
2011
|
|---|---|
| Resumo |
The new paradigm of therapy in rheumatoid arthritis is to aim toward early and complete remission, using a larger use of conventional DMARDs and biologic agents. The present recommendations were established through a consensus to help practitioners in their daily use of those agents, to reflect the current "best practice" in Switzerland. |
| Identificador |
https://serval.unil.ch/notice/serval:BIB_1626948634BD info:pmid:21557111 https://serval.unil.ch/resource/serval:BIB_1626948634BD.P001/REF http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_1626948634BD0 urn:nbn:ch:serval-BIB_1626948634BD0 |
| Idioma(s) |
eng |
| Fonte |
Swiss Medical Weekly141w13189 |
| Palavras-Chave | #rheumatoid arthritis; biologics; anti-TNF; treatment optimisation; guidelines; CONTROLLED-TRIAL; DOUBLE-BLIND; COMBINATION THERAPY; METHOTREXATE; MULTICENTER; OUTCOMES; AGENT; ETANERCEPT; INHIBITION; RITUXIMAB |
| Tipo |
info:eu-repo/semantics/review article |
| Formato |
application/pdf |
| Direitos |
info:eu-repo/semantics/openAccess Copying allowed only for non-profit organizations https://serval.unil.ch/disclaimer |
